Derrick Gingery of pharma-focused publication Pink Sheet, reported on X: “Breaking: The @US_FDA ‘s CDER announces Mike Davis, former team leader in the FDA Division of Psychiatry and current Usona Institute CMO, will become CDER deputy director.” Publicly-traded companies in the psychiatric drug space include atai Life Sciences (ATAI), Clearmind (CMND), Compass Pathways (CMPS), Cybin (CYBN), GH research (GHRS) and Mind Medicine (MNMD).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATAI:
- Trump Trade: President said to weigh possible U.S. strike against Iran
- Psychedelic advocates hopeful Trump administration will support space, STAT says
- Largest borrow rate increases among liquid names
- Psychedelic: Clearmind engages government, political affairs consulting firm
- Atai Life Sciences initiated with a Buy at Lucid Capital